We have all heard or know of someone who is taking the obesity drug but the exciting news is research going to take the obesity GLP-1 drugs for wider use. A science paper summary of the GLP-1 advances shows how researchers are focusing on other uses.
Ozempic and other GLP-1 receptor agonists have swept the world for obesity and type 2 diabetes. Their extended value is reducing inflammation and improving clinical outcomes in heart disease by 20% or more. Kidney diseases along with promising but less consistent evidence in liver diseases, while research in autoimmune diseases and dementia remains preliminary.
